CVE:RX BioSyent - RX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding BioSyent Inc. Please log in to your account or sign up in order to add this asset to your watchlist. C$7.33 +0.05 (+0.69%) (As of 03/21/2023 01:14 PM ET) Add Compare Share Share Today's RangeC$7.33▼C$7.3350-Day RangeC$7.14▼C$7.5052-Week RangeC$6.24▼C$10.00Volume200 shsAverage Volume2,196 shsMarket CapitalizationC$88.69 millionP/E Ratio14.96Dividend Yield2.18%Price TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesHeadlines About BioSyent (CVE:RX) StockBioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia. It also offers Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; and Proktis-M, a rectal suppository for the healing of the anus and rectum. In addition, it provides Combogesic for moderate acute pain and reduction of fever in adults; Protect-It, a non-chemical food-safe grain insecticide product used as a preventative treatment against insect infestations in stored grains; and Tibella, a hormone replacement therapy to treat vasomotor symptoms due to estrogen deficiency. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. was incorporated in 2006 and is headquartered in Mississauga, Canada.Read More Receive RX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioSyent and its competitors with MarketBeat's FREE daily newsletter. Email Address RX Stock News HeadlinesDecember 29, 2022 | nz.finance.yahoo.comA Look At The Fair Value Of BioSyent Inc. (CVE:RX)December 14, 2022 | finance.yahoo.comBioSyent Signs Exclusive Agreement for Oncology Supportive Care ProductMarch 21, 2023 | PressReach (Ad)Stocks Positioned For The YearThis breakthrough stock has bright future this decade.December 4, 2022 | finance.yahoo.comShareholders in BioSyent (CVE:RX) are in the red if they invested five years agoNovember 17, 2022 | finanznachrichten.deBioSyent Inc.: BioSyent Releases Q3 and YTD 2022 Financial ResultsOctober 17, 2022 | finance.yahoo.comAre BioSyent Inc.'s (CVE:RX) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?October 12, 2022 | finance.yahoo.comBioSyent Initiates First DividendSeptember 18, 2022 | reuters.comRX.V - Biosyent Inc | Stock Price & Latest News | ReutersMarch 21, 2023 | PressReach (Ad)Stocks Positioned For The YearThis breakthrough stock has bright future this decade.September 17, 2022 | cnet.com2023 Lexus RX First Drive Review: Turbo? Hybrid? Why Not Both?September 14, 2022 | finance.yahoo.comBioSyent to Present at the Virtual MicroCap Leadership SummitAugust 24, 2022 | seekingalpha.comBioSyent reports Q2 resultsAugust 23, 2022 | nz.finance.yahoo.comBioSyent Releases Q2 and H1 2022 Financial ResultsAugust 23, 2022 | finance.yahoo.comBioSyent Announces Adoption of Dividend PolicyJuly 6, 2022 | uk.finance.yahoo.comFactors that could predict the future for shares in BiosyentJune 27, 2022 | uk.finance.yahoo.comBioSyent (CVE:RX) shareholders have earned a 6.8% CAGR over the last three yearsMay 18, 2022 | globenewswire.comBioSyent Releases Financial Results for Q1 2022 - GlobeNewswireMay 18, 2022 | finance.yahoo.comBioSyent Releases Financial Results for Q1 2022 - Yahoo FinanceMay 11, 2022 | finance.yahoo.comBioSyent Schedules Q1 2022 Earnings Release for May 18, 2022 - Yahoo FinanceMay 10, 2022 | globenewswire.comBioSyent Schedules Q1 2022 Earnings Release for May 18, 2022 - GlobeNewswireMay 2, 2022 | finance.yahoo.comFeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Seventh Consecutive Year - Yahoo FinanceApril 28, 2022 | finance.yahoo.comBioSyent to Present at 2022 Bloom Burton & Co. Healthcare Investor Conference - Yahoo FinanceApril 26, 2022 | globenewswire.comBioSyent to Present at 2022 Bloom Burton & Co. Healthcare Investor Conference - GlobeNewswireApril 3, 2022 | au.finance.yahoo.comBioSyent Releases Financial Results for Fourth Quarter and Full Year 2021March 31, 2022 | globenewswire.comBioSyent Announces Grant of Restricted Share Units - GlobeNewswireMarch 29, 2022 | finance.yahoo.comFAX Capital Corp. Reports Fourth Quarter and 2021 Results - Yahoo FinanceMarch 9, 2022 | globenewswire.comBioSyent Releases Financial Results for Fourth Quarter and Full Year 2021 - GlobeNewswireSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive RX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioSyent and its competitors with MarketBeat's FREE daily newsletter. Email Address RX Company Calendar Last Earnings5/25/2017Today3/21/2023Next Earnings (Estimated)3/22/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeCVE Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolCVE:RX CUSIPN/A CIKN/A Webwww.biosyent.com Phone+1-905-2060013FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)C$0.49 Trailing P/E Ratio14.86 Forward P/E Ratio13.83 P/E GrowthN/ANet IncomeC$6.14 million Net Margins22.17% Pretax MarginN/A Return on Equity19.38% Return on Assets13.03% Debt Debt-to-Equity Ratio4.36 Current Ratio7.93 Quick Ratio6.91 Sales & Book Value Annual SalesC$27.68 million Price / Sales3.18 Cash FlowC$2.37 per share Price / Cash Flow3.07 Book ValueC$2.71 per share Price / Book2.69Miscellaneous Outstanding Shares12,100,000Free FloatN/AMarket CapC$88.09 million OptionableNot Optionable Beta0.78 Key ExecutivesMr. René C. Goehrum (Age 64)Chairman, CEO & Pres Comp: $542.38kMr. Robert J. MarchVP of Fin. & CFOMr. Joost van der MarkVP of Corp. Devel.Ms. Neelu AtwalDirector of HRMr. Alfred D'SouzaAdvisorKey CompetitorsDelta 9 CannabisCVE:NINEGreen Organic DutchmanTSE:TGODHEXOTSE:HEXOCipher PharmaceuticalsTSE:CPHWeedMDCVE:WMDView All CompetitorsInsidersBlair DriscollBought 25,000 shares on 6/30/2022Total: C$194,750.00 ($7.79/share)Sharan RaghubirSold 5,193 sharesTotal: C$39,622.59 ($7.63/share)View All Insider Transactions RX Stock - Frequently Asked Questions How have RX shares performed in 2023? BioSyent's stock was trading at C$7.00 at the beginning of 2023. Since then, RX stock has increased by 4.0% and is now trading at C$7.28. View the best growth stocks for 2023 here. When is BioSyent's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 22nd 2023. View our RX earnings forecast. How were BioSyent's earnings last quarter? BioSyent Inc. (CVE:RX) announced its quarterly earnings data on Thursday, May, 25th. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.08 by $0.02. The company earned $3.82 million during the quarter, compared to the consensus estimate of $4.80 million. BioSyent had a net margin of 22.17% and a trailing twelve-month return on equity of 19.38%. Is BioSyent a good dividend stock? BioSyent (CVE:RX) pays an annual dividend of C$0.16 per share and currently has a dividend yield of 2.24%. The dividend payout ratio is 32.65%. This payout ratio is at a healthy, sustainable level, below 75%. What other stocks do shareholders of BioSyent own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioSyent investors own include Aurora Cannabis (ACB), Canadian National Railway (CNR), Bank of Nova Scotia (BNS), Cross Timbers Royalty Trust (CRT), Dollarama (DOL), Enbridge (ENB), Gilead Sciences (GILD), National Bank of Canada (NA) and Air Canada (AC). What is BioSyent's stock symbol? BioSyent trades on the Canadian Venture Exchange (CVE) under the ticker symbol "RX." How do I buy shares of BioSyent? Shares of RX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What is BioSyent's stock price today? One share of RX stock can currently be purchased for approximately C$7.28. How much money does BioSyent make? BioSyent (CVE:RX) has a market capitalization of C$88.09 million and generates C$27.68 million in revenue each year. The company earns C$6.14 million in net income (profit) each year or C$0.49 on an earnings per share basis. How can I contact BioSyent? BioSyent's mailing address is 170 Attwell Dr Suite 520, ETOBICOKE, ON M9W 5Z5, Canada. The official website for the company is www.biosyent.com. The company can be reached via phone at +1-905-2060013. This page (CVE:RX) was last updated on 3/21/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.